Trial Profile
A phase 2, randomized, active comparator-controlled, dose-ranging study to evaluate the efficacy and safety of TAK-442 in subjects undergoing total knee replacement.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Letaxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 05 Dec 2009 Results have been presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.
- 19 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 19 Dec 2008 Planned number of patients changed from 1050 to 1045 as reported by ClinicalTrials.gov.